Director Eric Crombez sells Abeona Therapeutics (ABEO) shares to cover taxes

Rhea-AI Filing Summary

Abeona Therapeutics director Eric Crombez reported a sale of company stock. On 02/02/2026, he sold 16,284 shares of Abeona Therapeutics common stock at a weighted average price of $5.0906 per share in market transactions.

According to the disclosure, this sale was made to cover tax obligations arising from the vesting of restricted stock awards. After these transactions, Crombez beneficially owned 63,456 shares of Abeona Therapeutics common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crombez Eric

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		S(1)		16,284	D	$5.0906(2)	63,456	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.09 to $5.12 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Eric Crombez	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Abeona Therapeutics (ABEO) director Eric Crombez report on this Form 4?

Eric Crombez reported selling 16,284 shares of Abeona Therapeutics common stock. The transaction occurred on February 2, 2026, and was reported as a disposition of non-derivative securities under transaction code “S” with direct ownership status after the sale.

At what price did Eric Crombez sell Abeona Therapeutics (ABEO) shares?

The reported weighted average sale price was $5.0906 per share. The filing notes the shares were sold in multiple transactions, with individual prices ranging from $5.09 to $5.12 per share, all occurring on February 2, 2026, in open-market trades.

How many Abeona Therapeutics (ABEO) shares does Eric Crombez own after the sale?

After the reported sale, Eric Crombez beneficially owned 63,456 shares of Abeona Therapeutics common stock. The filing states these holdings are directly owned, reflecting his remaining equity position following the 16,284-share disposition on February 2, 2026.

Why did Eric Crombez sell Abeona Therapeutics (ABEO) shares in this transaction?

The filing explains the sale was executed to cover tax obligations tied to the vesting of restricted stock awards. This means part of the vested equity was sold specifically to satisfy related tax liabilities rather than as a discretionary sale of investment holdings.

What does the weighted average price range mean in this Abeona Therapeutics (ABEO) Form 4?

The filing reports a weighted average price of $5.0906, with individual sale prices between $5.09 and $5.12. This indicates multiple trades occurred within that range, and the insider offers to provide detailed trade-by-trade pricing information to the issuer or regulators upon request.

What is Eric Crombez’s relationship to Abeona Therapeutics (ABEO)?

Eric Crombez is identified as a director of Abeona Therapeutics. The Form 4 indicates he is not listed as an officer or 10% owner, and the reported transaction relates to his role as a director with directly held common stock in the company.